Adverts

Open Access Articles- Top Results for Yttrium (90Y) clivatuzumab tetraxetan

Yttrium (90Y) clivatuzumab tetraxetan

</th></tr>
Yttrium (90Y) clivatuzumab tetraxetan?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target MUC1
Clinical data
Identifiers
943976-23-6 7pxN
None
Chemical data
Formula C6496H9952N1716O2014S44
145.7 kDa
 14pxN (what is this?)  (verify)

Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody designed for the treatment of pancreatic cancer.[1] The antibody itself, clivatuzumab, is conjugated with tetraxetan, a chelator for yttrium-90,[2] a radioisotope which destroys the tumour cells.

The drug was developed by Immunomedics, Inc.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan" (PDF). American Medical Association. 
  2. ^ WHO Drug Information


Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.